Immunogenicity of Synthetic Peptide Malaria Vaccines
合成肽疟疾疫苗的免疫原性
基本信息
- 批准号:7409058
- 负责人:
- 金额:$ 47.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-09-15 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntibodiesAntibody FormationArtemisininsAttenuatedB-Lymphocyte EpitopesBiological AssayBloodCellsClassCombination Drug TherapyComplexCore ProteinDevelopmentEpitopesErythrocytesGoalsGoldGrantHIVHepatitis BHepatitis B Core AntigenHepatitis B VirusHumanHuman VolunteersHumoral ImmunitiesImmuneImmune responseImmunityImmunizationIn VitroInsecticidesInterferonsKnowledgeLife Cycle StagesMalariaMalaria VaccinesMediatingMinorModelingModificationMonkeysMorbidity - disease rateMusParasitesPeptide VaccinesPeptidesPhasePhase I Clinical TrialsPhase II Clinical TrialsPlasmodiumPopulationPublic HealthRadiationRecombinantsResistanceRiskSchemeSpecificitySporozoitesStagingStandards of Weights and MeasuresSterilitySubunit VaccinesSurface AntigensT-LymphocyteTestingTh1 CellsTransgenic OrganismsVaccine DesignVaccinesViralVirus-like particleartemisininebasecircumsporozoitecircumsporozoite proteincostcytokineextracellularimmunogenicimmunogenicityin vivomortalitypathogenpre-clinicalresponsesynthetic peptidevaccine developmentvaccine efficacyvaccine-induced immunityvirus corevolunteer
项目摘要
DESCRIPTION (provided by applicant): Plasmodium parasites cause malaria morbidity and mortality in over 40% of the worlds population. Despite a complex parasite life cycle, immunization with irradiated sporozoites can elicit sterile immunity in mice, monkeys and humans, providing a gold standard for a pre-erythrocytic stage malaria vaccine. Since sporozoites cannot be produced in vitro, efforts have focused on developing subunit vaccines that elicit immune responses comparable to irradiated sporozoites. Over the past grant period, we have shown that synthetic peptides and hepatitis B virus core protein virus-like particles (VLP) containing minimal P. falciparum CS protein epitopes, were safe and immunogenic in preclinical and Phase I trials. In the current grant, the fine specificity and function of antibody and cells elicited in volunteers immunized with ICC-1132, a VLP expressing P. falciparum CS repeats and the universal T* Th epitope, will be examined (Specific Aim 1). The protective efficacy of this VLP and linear peptide vaccines will be compared and the immune mechanisms of protection defined using transgenic parasites expressing P. falciparum CS epitopes (Specific Aim 2). In an effort to optimize humoral and cellular responses, truncated T and B cell epitopes will be tested as peptide vaccines (Specific Aim 2) and heterologous prime:boost immunization strategies, using VLP and peptides, will be assayed for protective efficacy (Specific Aim 3). A major limitation in P. falciparum vaccine Phase II trials is the inability to dissect immune responses of human volunteers to define correlates of protective immunity. We will therefore construct P. berghei transgenics expressing P. falciparum CS major or minor repeats, or the universal T* epitope, to establish small animal models for analysis of protective immune mechanisms elicited by P. falciparum CS subunit vaccines (Specific Aim 4). The information gained from these studies will be applicable to development of vaccines against malaria blood stage parasites, as well as viral and bacterial pathogens that require strong humoral responses for protective immunity.
描述(申请人提供):疟疾寄生虫导致疟疾发病率和死亡率超过40%的世界人口。尽管寄生虫有一个复杂的生命周期,但用辐照过的子孢子免疫可以在小鼠、猴子和人类身上引起无菌免疫,为红细胞前期疟疾疫苗提供了黄金标准。由于子孢子不能在体外产生,因此努力的重点是开发亚单位疫苗,这种疫苗可以引起与受辐射的子孢子相当的免疫反应。在过去的资助期间,我们已经在临床前和I期试验中证明了含有最小恶性疟原虫CS蛋白表位的合成肽和乙肝病毒核心蛋白病毒样颗粒(VLP)是安全和免疫的。在目前的赠款中,将检测ICC-1132、表达恶性疟原虫CS重复序列的VLP和通用T*Th表位免疫志愿者所诱导的抗体和细胞的良好特异性和功能(特定目标1)。将比较这种VLP疫苗和线性多肽疫苗的保护效果,并使用表达恶性疟原虫CS表位的转基因寄生虫来确定保护的免疫机制(特定目标2)。为了优化体液和细胞反应,截短的T和B细胞表位将作为多肽疫苗进行测试(特定目标2),并将测试使用VLP和多肽的异源PRIME免疫策略的保护效果(特定目标3)。恶性疟原虫疫苗第二阶段试验的一个主要限制是无法剖析人类志愿者的免疫反应,以确定保护性免疫的相关性。因此,我们将构建表达恶性疟原虫CS主要或次要重复序列或通用T*表位的转基因伯氏疟原虫,以建立用于分析恶性疟原虫CS亚单位疫苗诱导的保护性免疫机制的小动物模型(特定目标4)。从这些研究中获得的信息将适用于疟疾血液期寄生虫疫苗的开发,以及需要强烈体液反应以进行保护性免疫的病毒和细菌病原体的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth H Nardin其他文献
Elizabeth H Nardin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth H Nardin', 18)}}的其他基金
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
8126073 - 财政年份:2010
- 资助金额:
$ 47.48万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
7899536 - 财政年份:2009
- 资助金额:
$ 47.48万 - 项目类别:
IMMUNOGENICITY OF SYNTHETIC POLYOXIME MALARIA VACCINES
合成多肟疟疾疫苗的免疫原性
- 批准号:
6374126 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
IMMUNOGENICITY OF SYNTHETIC POLYOXIME MALARIA VACCINES
合成多肟疟疾疫苗的免疫原性
- 批准号:
6170713 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
Immunogenicity of Synthetic Peptide Malaria Vaccines
合成肽疟疾疫苗的免疫原性
- 批准号:
6985967 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
IMMUNOGENICITY OF SYNTHETIC POLYOXIME MALARIA VACCINES
合成多肟疟疾疫苗的免疫原性
- 批准号:
6534146 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
Immunogenicity of Synthetic Peptide Malaria Vaccines
合成肽疟疾疫苗的免疫原性
- 批准号:
7092032 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
Immunogenicity of Synthetic Peptide Malaria Vaccines
合成肽疟疾疫苗的免疫原性
- 批准号:
7686245 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
IMMUNOGENICITY OF SYNTHETIC POLYOXIME MALARIA VACCINES
合成多肟疟疾疫苗的免疫原性
- 批准号:
2856111 - 财政年份:1999
- 资助金额:
$ 47.48万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 47.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 47.48万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 47.48万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 47.48万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 47.48万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 47.48万 - 项目类别: